Scaling-up HIV Treatment Programmes in Resource-limited Settings: The Rural Haiti Experience

Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
AIDS (Impact Factor: 5.55). 07/2004; 18 Suppl 3(Supplement 3):S21-5. DOI: 10.1097/00002030-200406003-00005
Source: PubMed


To scale-up a successful HIV/AIDS treatment project and provide comprehensive care to an entire Département du Centre (population 550 000) in rural Haiti, thereby demonstrating that community-based treatment of HIV is feasible and highly effective in resource-limited settings, and serving as a successful model for others to replicate.
In the Département du Centre of rural Haiti comprehensive HIV and tuberculosis treatment is provided free of charge to anyone who presents for care. All those who meet clinical enrolment criteria are treated with highly active antiretroviral therapy (HAART).
HAART was provided in the context of a comprehensive programme of HIV, tuberculosis (TB), sexually transmitted disease (STD) of the project, treatment and prevention, and women's health services at four sites in the first year. At each site, the medical facility was renovated, additional staff were hired as needed, and a network of accompagnateurs (community health workers) was established throughout the surrounding villages to serve as a link with the community, and to provide directly observed treatment (DOT).
In the first year of programme scale-up, over 8000 patients were followed for HIV, and over 1050 were treated with DOT HAART. Adherence to HAART was very high, and clinical outcomes were excellent: all patients responded with weight gain and improved functional capacity, and fewer than 5% required medication changes due to side effects. Viral load was tested among a subset of patients showing that 86% had undetectable viral loads.
Community-based care of AIDS has been highly effective in rural Haiti. With more international financial support for HIV/AIDS treatment in resource-limited settings, there should be no barriers to access to life-saving HAART for those who need it most.

Download full-text


Available from: Fernet Léandre,
  • Source
    • "In rural Rwanda, CHWs have maintained high retention (92%) in care and improved viral loads among HIV-infected patients (Rich et al., 2012). While there is some evidence that a dose-response relationship may exist between CHW exposure and improvement in HAART adherence (Khanlou et al., 2003), in general, CHWs have successfully performed basic skills that have resulted in improved outcomes among PLWHA (Bussmann et al., 2008; Koenig, Leandre, & Farmer, 2004; Massaquoi et al., 2008). Controversy over whether CHWs should volunteer or be paid for their services continues to be discussed in the literature, yet disadvantages of not remunerating CHWs have gained greater attention (Kenya et al., 2011). "

    Journal of HIV/AIDS & Social Services 10/2014; 13(4):330-336. DOI:10.1080/15381501.2014.964536
  • Source
    • "Even though socioeconomic status has been associated with HIV treatment outcomes [44] our study surprisingly did not suggest an association between socio-economic or behavioural predictors of virologic failure. However, participants from the NW region, and patients residing far from treatment centres were more likely to experience virologic failure. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Contemporary data on the immunologic, haematologic and virologic responses and predictors of virologic failure after initiation of free antiretroviral treatment in Cameroon are needed to evaluate the current treatment-monitoring algorithm and to complement efforts to scale-up and improve on the management of HIV infections. This was a cross-sectional study conducted between October 2010 and June 2012. A total of 951 participants aged 18-74 years were recruited from selected approved HIV treatment centres of the Northwest and Southwest regions. This comprised 247 males and 704 females. Demographic, self-reported risk behaviours and socioeconomic data were obtained using a structured questionnaire. Full blood and CD4 + T-cell counts were done using standard automated techniques. Determination of viral load (VL) was done using Abbott RealTime HIV-1 m2000TM system. Data was analysed using SPSS version 17. The statistical significance level was P < 0.05. The median duration of antiretroviral therapy (ART) was 24 months. The population mean CD4 + T-cell count was 255.3 cells/muL [95% CI, 236.8 - 273.9]. Overall, 45.9%, 43.8% and 10.2% of the participants had CD4 + T-cell counts of < 200 cells/muL, 200-499 cells/muL and > 500 cells/muL respectively. Anaemia was present in 26.2% of the participants with 62.3%, 25.7% and 12% described as mild, moderate and severe anaemia respectively. Virologic failure occurred in 23.2% of the participants with 12.3% having VL > 10,000 RNA copies/mL. Meanwhile 76.8% of patients attained adequate viral suppression with 40.8% having undetectable viral load. The age group 18-29 years (p = 0.024), co-infection with tuberculosis (p = 0.014), anaemia (p = 0.028) and distance from the treatment centre (p = 0.011) independently predicted virologic failure. The majority of the participants achieved adequate viral suppression after >= 6 months of ART. Despite these favourable immuno-haematologic and virologic outcomes, the National AIDS Control Program should step-up efforts to improve on antiretroviral drug distribution, as well as proper assessment and management of anaemia, foster early diagnosis and treatment of tuberculosis and enhance treatment adherence counselling especially in younger patients.
    Infectious Diseases of Poverty 01/2014; 3(1):5. DOI:10.1186/2049-9957-3-5 · 4.11 Impact Factor
  • Source
    • "Even though socio-economic status have been linked to HIV treatment outcomes [42-44], our study surprisingly did not suggest an association between socio-economic or behavioral predictors to virologic failure. The most important impact of SES on HIV treatment is on the cost of the HIV drugs, laboratory work-up and the commodities. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Predictors of immuno-virologic outcomes and discordance and their associations with clinical, demographic, socio-economic and behavioral risk factors are not well described in Nigeria since HIV viral load testing is not routinely offered in public HIV treatment programs. The HACART study was a multi-center observational clinic-based cohort study of 2585 adults who started HAART between April 2008 and February 2009. A total of 628 patients were randomly selected at 12 months for immuno-virologic analyses. Virologic suppression rate (<400 copies/ml) was 76.7%, immunologic recovery rate (CD4 change from baseline ≥50 cells/mm3) was 77.4% and immuno-virologic discordance rate was 33%. In multivariate logistic regression, virologic failure was associated with age <30 years (OR 1.79; 95% CI: 1.17-2.67, p=0.03), anemia (Hemoglobin < 10 g/dl) (OR 1.71; 95% CI: 1.22-2.61, p=0.03), poor adherence (OR 3.82; 95% CI: 2.17-5.97, p=0.001), and post-secondary education (OR 0.60; 95% CI: 0.30-0.86, p=0.02). Immunologic failure was associated with male gender (OR 1.46; 95% CI: 1.04-2.45, p=0.04), and age <30 years (OR 1.50; 95% CI: 1.11-2.39, p=0.03). Virologic failure with immunologic success (VL-/CD4+) was associated with anemia (OR 1.80; 95% CI: 1.13-2.88, p=0.03), poor adherence (OR 3.90; 95% CI: 1.92-8.24, p=0.001), and post-secondary education (OR 0.40; 95% CI: 0.22-0.68, p=0.005). Although favorable immuno-virologic outcomes could be achieved in this large ART program, immuno-virologic discordance was observed in a third of the patients. Focusing on intensified treatment preparation and adherence, young patients, males, persons with low educational status and most importantly baseline anemia assessment and management may help address predictors of poor immuno-virologic outcomes, and improve overall HIV program impact. Viral load testing in addition to the CD4 testing should be considered to identify, characterize and address negative immuno-virologic outcomes and discordance.
    BMC Infectious Diseases 03/2013; 13(1):113. DOI:10.1186/1471-2334-13-113 · 2.61 Impact Factor
Show more